CA3075146A1 - Procedes et utilisations de composes pour le traitement de troubles choriocapillaires - Google Patents
Procedes et utilisations de composes pour le traitement de troubles choriocapillaires Download PDFInfo
- Publication number
- CA3075146A1 CA3075146A1 CA3075146A CA3075146A CA3075146A1 CA 3075146 A1 CA3075146 A1 CA 3075146A1 CA 3075146 A CA3075146 A CA 3075146A CA 3075146 A CA3075146 A CA 3075146A CA 3075146 A1 CA3075146 A1 CA 3075146A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- choriocapillaris
- effective amount
- therapeutically effective
- need
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 111
- 238000011282 treatment Methods 0.000 title description 35
- 150000001875 compounds Chemical class 0.000 title description 17
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 99
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 38
- 210000005166 vasculature Anatomy 0.000 claims abstract description 31
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 111
- 208000002780 macular degeneration Diseases 0.000 claims description 93
- 102100037424 Receptor-type tyrosine-protein phosphatase beta Human genes 0.000 claims description 87
- 101710101345 Receptor-type tyrosine-protein phosphatase beta Proteins 0.000 claims description 87
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims description 82
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims description 82
- 239000012190 activator Substances 0.000 claims description 72
- 239000003112 inhibitor Substances 0.000 claims description 70
- 230000001965 increasing effect Effects 0.000 claims description 46
- 206010063381 Polypoidal choroidal vasculopathy Diseases 0.000 claims description 44
- 230000010412 perfusion Effects 0.000 claims description 42
- 210000003161 choroid Anatomy 0.000 claims description 36
- 208000035475 disorder Diseases 0.000 claims description 20
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 19
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 19
- 208000008069 Geographic Atrophy Diseases 0.000 claims description 15
- 108010048154 Angiopoietin-1 Proteins 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 12
- 150000003384 small molecules Chemical class 0.000 claims description 11
- 108010092511 Vasculotide Proteins 0.000 claims description 10
- 208000010837 Diabetic eye disease Diseases 0.000 claims description 9
- 229960002833 aflibercept Drugs 0.000 claims description 9
- 230000027455 binding Effects 0.000 claims description 8
- 230000001976 improved effect Effects 0.000 claims description 8
- 108010009906 Angiopoietins Proteins 0.000 claims description 7
- 108010081667 aflibercept Proteins 0.000 claims description 7
- 230000004377 improving vision Effects 0.000 claims description 7
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 claims description 6
- 108700028369 Alleles Proteins 0.000 claims description 6
- 102000009840 Angiopoietins Human genes 0.000 claims description 6
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims description 6
- 230000001270 agonistic effect Effects 0.000 claims description 6
- 229960003876 ranibizumab Drugs 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 108700036276 KH902 fusion Proteins 0.000 claims description 5
- 101100371160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) TSL1 gene Proteins 0.000 claims description 5
- 229960000397 bevacizumab Drugs 0.000 claims description 5
- 229960000106 biosimilars Drugs 0.000 claims description 5
- 229950000025 brolucizumab Drugs 0.000 claims description 5
- 229950005748 conbercept Drugs 0.000 claims description 5
- 229940116862 faricimab Drugs 0.000 claims description 5
- 230000003606 oligomerizing effect Effects 0.000 claims description 5
- 229940005014 pegaptanib sodium Drugs 0.000 claims description 5
- 229960002633 ramucirumab Drugs 0.000 claims description 5
- 102000009088 Angiopoietin-1 Human genes 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 18
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 16
- 230000011664 signaling Effects 0.000 description 16
- 230000018109 developmental process Effects 0.000 description 15
- 102100034594 Angiopoietin-1 Human genes 0.000 description 14
- 238000011161 development Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 12
- 238000011813 knockout mouse model Methods 0.000 description 12
- 230000002792 vascular Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 210000001508 eye Anatomy 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 210000002752 melanocyte Anatomy 0.000 description 9
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 8
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000002648 combination therapy Methods 0.000 description 8
- 230000000670 limiting effect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000000933 neural crest Anatomy 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 238000002583 angiography Methods 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 230000004438 eyesight Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 6
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 230000003511 endothelial effect Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000012014 optical coherence tomography Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102100034608 Angiopoietin-2 Human genes 0.000 description 5
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 5
- 101150102644 Angpt1 gene Proteins 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 4
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 108091008695 photoreceptors Proteins 0.000 description 4
- 210000001747 pupil Anatomy 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 230000004393 visual impairment Effects 0.000 description 4
- 101150040698 ANGPT2 gene Proteins 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- 102100038566 Endomucin Human genes 0.000 description 3
- 101001030622 Homo sapiens Endomucin Proteins 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 230000008093 supporting effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 2
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100039270 Ribulose-phosphate 3-epimerase Human genes 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 208000011325 dry age related macular degeneration Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 2
- 239000002525 vasculotropin inhibitor Substances 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000014087 Chorioretinal disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 235000004035 Cryptotaenia japonica Nutrition 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000028523 Hereditary Complement Deficiency disease Diseases 0.000 description 1
- 101000595198 Homo sapiens Podocalyxin Proteins 0.000 description 1
- 101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000032028 Microvascular Rarefaction Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101150031207 NOS3 gene Proteins 0.000 description 1
- 241001602876 Nata Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102100035591 POU domain, class 2, transcription factor 2 Human genes 0.000 description 1
- 101710084411 POU domain, class 2, transcription factor 2 Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102100036031 Podocalyxin Human genes 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010090091 TIE-2 Receptor Proteins 0.000 description 1
- 102000012753 TIE-2 Receptor Human genes 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000007641 Trefoil Factors Human genes 0.000 description 1
- 235000015724 Trifolium pratense Nutrition 0.000 description 1
- 102000008790 VE-cadherin Human genes 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000038018 age-related macular disease Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000015624 blood vessel development Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 108010018828 cadherin 5 Proteins 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 201000002388 complement deficiency Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 101150047356 dec-1 gene Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229940051306 eylea Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 229940092110 macugen Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 230000010060 microvascular dysfunction Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000026341 positive regulation of angiogenesis Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001686 pro-survival effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004262 retinal health Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000002301 subretinal fluid Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008427 tissue turnover Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000006453 vascular barrier function Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000009441 vascular protection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229940036061 zaltrap Drugs 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962878366P | 2019-07-25 | 2019-07-25 | |
| US62/878,366 | 2019-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3075146A1 true CA3075146A1 (fr) | 2021-01-25 |
Family
ID=74222132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3075146A Abandoned CA3075146A1 (fr) | 2019-07-25 | 2020-03-11 | Procedes et utilisations de composes pour le traitement de troubles choriocapillaires |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA3075146A1 (fr) |
-
2020
- 2020-03-11 CA CA3075146A patent/CA3075146A1/fr not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rudraraju et al. | Regulation of blood-retinal barrier cell-junctions in diabetic retinopathy | |
| Park-Windhol et al. | Disorders of vascular permeability | |
| Shen et al. | Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature | |
| Amadio et al. | Targeting VEGF in eye neovascularization: What's new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development | |
| Byeon et al. | Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/Akt | |
| Zampros et al. | Antivascular endothelial growth factor agents for neovascular age‐related macular degeneration | |
| Li et al. | A small molecule inhibitor of VE-PTP activates Tie2 in Schlemm's canal increasing outflow facility and reducing intraocular pressure | |
| ES2606627T3 (es) | Anticuerpos específicos anti-CD160 para el tratamiento de trastornos oculares basados en la neoangiogénesis | |
| AU2013245630A1 (en) | Treatment of ischemic retinopathies | |
| Iwase et al. | Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit | |
| Casciano et al. | The role of the mTOR pathway in diabetic retinopathy | |
| Malhi et al. | Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy | |
| Ren et al. | The effect of CM082, an oral tyrosine kinase inhibitor, on experimental choroidal neovascularization in rats | |
| Kim et al. | Emerging opportunities for C3 inhibition in the eye | |
| CA3075146A1 (fr) | Procedes et utilisations de composes pour le traitement de troubles choriocapillaires | |
| Toledano et al. | A Sema3C mutant resistant to cleavage by furin (FR-Sema3C) inhibits choroidal neovascularization | |
| KR20220005440A (ko) | 색소 상피-유래 인자(pedf)를 사용하는 질환 치료 방법 | |
| Wang et al. | Receptor tyrosine kinase inhibitors AG013764 and AG013711 reduce choroidal neovascularization in rat eye | |
| Stewart | PDGF: ophthalmology's next great target | |
| Gao et al. | Flt3 regulation in the mononuclear phagocyte system promotes ocular neovascularization | |
| Toledano et al. | A SEMA3E mutant resistant to cleavage by furins (UNCL-SEMA3E) inhibits choroidal neovascularization | |
| Malhi et al. | New Developments in Translational Microcirculatory Research: Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy | |
| US20230338483A1 (en) | Method for the treatment of a disease using pigment epithelium-derived factor (pedf) | |
| US20210361747A1 (en) | Recombinant thrombomodulin domain 1 for use in treating eye diseases associated with pathological ocular angiogenesis | |
| Ali et al. | Effect of sunitinib in treatment of retinal angiogenesis induced by VEGF165 in rabbit's eyes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20230912 |